Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
Sponsor: Roswell Park Cancer Institute
Summary
This study investigates the clinical course of CDK4/6 inhibitor treated patients in the real-world setting among patients with breast cancer. CDK4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy, from patients with breast cancer that has spread to the other places in the body (metastatic) may help doctors learn more about cancer and the development of drug resistance in patients, and predict how well patients will respond to treatment.
Official title: The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
700
Start Date
2020-07-03
Completion Date
2035-07-03
Last Updated
2025-11-13
Healthy Volunteers
No
Conditions
Interventions
Cytology Specimen Collection Procedure
Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
Diagnostic Laboratory Biomarker Analysis
Correlative studies
Medical Chart Review
Patient's electronic health records are reviewed
Locations (1)
Roswell Park Cancer Institute
Buffalo, New York, United States